A Pharmacokinetic and Pharmacodynamic Study of Oral Oxycodone in a Human Experimental Pain Model of Hyperalgesia

详细信息    查看全文

• 作者：Anne E. Olesen (1) (2)
  Richard Upton (3)
  David J. R. Foster (4)
  Camilla Staahl (1) (2)
  Lona L. Christrup (5)
  Lars Arendt-Nielsen (2)
  Professor Asbj?rn M. Drewes (1) (2)
  
• 刊名：Clinical Pharmacokinetics
• 出版年：2010
• 出版时间：December 2010
• 年：2010
• 卷：49
• 期：12
• 页码：817-827
• 全文大小：206KB
• 参考文献：1. Trescot AM, Datta S, Lee M, et al. Opioid pharmacology. Pain Physician 2008 Mar; 11: 133-3
  2. Holtman JR, Wala EP. Characterization of the antinociceptive effect of oxycodone in male and female rats. Pharmacol Biochem Behav 2006 Jan; 83: 100- g/10.1016/j.pbb.2005.12.013">CrossRef
  3. Nielsen CK, Ross FB, Lotfipour S, et al. Oxycodone and morphine have distinctly different pharmacological profiles: radioligand binding and behavioural studies in two rat models of neuropathic pain. Pain 2007 Dec; 132: 289-00 g/10.1016/j.pain.2007.03.022">CrossRef
  4. Nozaki C, Saitoh A, Kamei J. Characterization of the antinociceptive effects of oxycodone in diabetic mice. Eur J Pharmacol 2006 Mar; 535: 145-1 g/10.1016/j.ejphar.2006.02.002">CrossRef
  5. Nozaki C, Saitoh A, Tamura N, et al. Antinociceptive effect of oxycodone in diabetic mice. Eur J Pharmacol 2005 Nov; 524: 75- g/10.1016/j.ejphar.2005.09.051">CrossRef
  6. Ross FB, Smith MT. The intrinsic antinociceptive effects of oxycodone appear to be kappa-opioid receptor mediated. Pain 1997 Nov; 73: 151- g/10.1016/S0304-3959(97)00093-6">CrossRef
  7. Kalso E. Oxycodone. J Pain Symptom Manage 2005 May; 29: S47-6 g/10.1016/j.jpainsymman.2005.01.010">CrossRef
  8. Labuz D, Mousa SA, Schafer M, et al. Relative contribution of peripheral versus central opioid receptors to antinociception. Brain Res 2007 Jul; 1160: 30- g/10.1016/j.brainres.2007.05.049">CrossRef
  9. Stein C. Peripheral mechanisms of opioid analgesia. Anesth Analg 1993 Jan; 76: 182-1 g/10.1213/00000539-199301000-00031">CrossRef
  10. Burton MB, Gebhart GF. Effects of kappa-opioid receptor agonists on responses to colorectal distension in rats with and without acute colonic inflammation. J Pharmacol Exp Ther 1998 May; 285: 707-5
  11. De Schepper HU, Cremonini F, Park MI, et al. Opioids and the gut: pharmacology and current clinical experience. Neurogastroenterol Motil 2004 Aug; 16: 383-4 g/10.1111/j.1365-2982.2004.00513.x">CrossRef
  12. Staahl C, Christrup LL, Andersen SD, et al. A comparative study of oxycodone and morphine in a multi-modal, tissue-differentiated experimental pain model. Pain 2006 Jul; 123: 28-6 g/10.1016/j.pain.2006.02.006">CrossRef
  13. Staahl C, Upton R, Foster DJ, et al. Pharmacokinetic-pharmacodynamic modeling ofmorphine and oxycodone concentrations and analgesic effectin a multimodal experimental pain model. J Clin Pharmacol 2008 May; 48: 619-1 g/10.1177/0091270008314465">CrossRef
  14. Schafer M. Peripheral opioid analgesia: from experimental to clinical studies. Curr Opin Anaesthesiol 1999 Oct; 12: 603- g/10.1097/00001503-199910000-00019">CrossRef
  15. Stein C, Machelska H, Schafer M. Peripheral analgesic and antiinflammatory effects of opioids. Z Rheumatol 2001 Dec; 60: 416-4 g/10.1007/s003930170004">CrossRef
  16. Sengupta JN, Snider A, Su X, et al. Effects of kappa opioids in the inflamed rat colon. Pain 1999 Feb; 79: 175-5 g/10.1016/S0304-3959(98)00175-4">CrossRef
  17. Hassan AH, Ableitner A, Stein C, et al. Inflammation of the rat paw enhances axonal transport of opioid receptors in the sciatic nerve and increases their density in the inflamed tissue. Neuroscience 1993 Jul; 55: 185-5 g/10.1016/0306-4522(93)90465-R">CrossRef
  18. Curatolo M, Arendt-Nielsen L, Petersen-Felix S. Central hypersensitivity in chronic pain: mechanisms and clinical implications. Phys Med Rehabil Clin N Am 2006 May; 17: 287-02 g/10.1016/j.pmr.2005.12.010">CrossRef
  19. Arendt-Nielsen L, Curatolo M, Drewes A. Human experimental pain models in drug development: translational pain research. Curr Opin Investig Drugs 2007 Jan; 8: 41-3
  20. Hammer J, Vogelsang H. Characterization of sensations induced by capsaicin in the upper gastrointestinal tract. Neurogastroenterol Motil 2007 Apr; 19: 279-7 g/10.1111/j.1365-2982.2007.00900.x">CrossRef
  21. Drewes AM, Schipper KP, Dimcevski G, et al. Multi-modal induction and assessment of allodynia and hyperalgesia in the human oesophagus. Eur J Pain 2003; 7: 539-9 g/10.1016/S1090-3801(03)00053-3">CrossRef
  22. Willert RP, Delaney C, Kelly K, et al. Exploring the neurophysiological basis of chest wall allodynia induced by experimental oesophageal acidificationevidenceof central sensitization. Neurogastroenterol Motil 2007 Apr; 19: 270- g/10.1111/j.1365-2982.2006.00890.x">CrossRef
  23. Olesen AE, Staahl C, Brock C, et al. Evoked human oesophageal hyperalgesia: a potential tool for analgesic evaluation? Basic Clin Pharmacol Toxicol 2009 Aug; 105: 126-6 g/10.1111/j.1742-7843.2009.00422.x">CrossRef
  24. Drewes AM, Gregersen H, Arendt-Nielsen L. Experimental pain in gastroenterology: a reappraisal of human studies. Scand J Gastroenterol 2003 Nov; 38: 1115-0 g/10.1080/00365520310004399">CrossRef
  25. Staahl C, Reddy H, Andersen SD, et al. Multi-modal and tissue-differentiated experimental pain assessment: reproducibility ofanew concept for assessment of analgesics. Basic Clin Pharmacol Toxicol 2006 Feb; 98: 201-1 g/10.1111/j.1742-7843.2006.pto_211.x">CrossRef
  26. Jespersen A, Dreyer L, Kendall S, et al. Computerized cuff pressure algometry: a new method to assess deep-tissue hypersensitivity infibromyalgia. Pain 2007 Sep; 131: 57-2 g/10.1016/j.pain.2006.12.012">CrossRef
  27. Polianskis R, Graven-Nielsen T, Arendt-Nielsen L. Computer-controlled pneumatic pressure algometry: a new technique for quantitative sensory testing. Eur J Pain 2001; 5: 267-7 g/10.1053/eujp.2001.0245">CrossRef
  28. Kass R, Raftery A. Bayes factors. J Am Stat Assoc 1995; 90: 773-5 g/10.1080/01621459.1995.10476572">CrossRef
  29. Savic RM, Jonker DM, Kerbusch T, et al. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn 2007 Oct; 34: 711-6 g/10.1007/s10928-007-9066-0">CrossRef
  30. Sarkar S, Woolf CJ, Hobson AR, et al. Perceptual wind-up in the human oesophagus is enhanced by central sensitisation. Gut 2006 Jul; 55: 920- g/10.1136/gut.2005.073643">CrossRef
  31. Frokjaer JB, Andersen SD, Gale J, et al. An experimental study of viscerovisceral hyperalgesia using an ultrasound-based multimodal sensory testing approach. Pain 2005 Dec; 119: 191-00 g/10.1016/j.pain.2005.09.031">CrossRef
  32. Stanfa L, Dickenson A. Spinal opioid systems in inflammation. Inflamm Res 1995 Jun; 44: 231-1 g/10.1007/BF01782974">CrossRef
  33. Riviere PJ. Peripheral kappa-opioid agonists for visceral pain. Br J Pharmacol 2004 Apr; 141: 1331- g/10.1038/sj.bjp.0705763">CrossRef
  34. Stein C. The control of pain in peripheral tissue by opioids. N Engl J Med 1995 Jun; 332: 1685-0 g/10.1056/NEJM199506223322506">CrossRef
  35. Janson W, Stein C. Peripheral opioid analgesia. Curr Pharm Biotechnol 2003 Aug; 4: 270- g/10.2174/1389201033489766">CrossRef
  36. Foster D, Upton R, Christrup L, et al. Pharmacokinetics and pharmacodynamics of intranasal versus intravenous fentanyl in patients with pain after oral surgery. Ann Pharmacother 2008 Oct; 42: 1380- g/10.1345/aph.1L168">CrossRef
  37. Lalovic B, Kharasch E, Hoffer C, et al. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther 2006 May; 79: 461-9 g/10.1016/j.clpt.2006.01.009">CrossRef
  38. Leow KP, Smith MT, Watt JA, et al. Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration. Ther Drug Monit 1992 Dec; 14: 479-4 g/10.1097/00007691-199212000-00008">CrossRef
  39. Mandema JW, Kaiko RF, Oshlack B, et al. Characterization and validation of a pharmacokinetic model for controlled-release oxycodone. Br J Clin Pharmacol 1996 Dec; 42: 747-6 g/10.1046/j.1365-2125.1996.00481.x">CrossRef
  40. Virk MS, Williams JT. Agonist-specific regulation of mu-opioid receptor desensitization and recovery from desensitization. Mol Pharmacol 2008 Apr; 73: 1301- g/10.1124/mol.107.042952">CrossRef
  41. Coller JK, Christrup LL, Somogyi AA. Role of active metabolites in the use of opioids. Eur J Clin Pharmacol 2009 Feb; 65: 121-9 g/10.1007/s00228-008-0570-y">CrossRef
  42. Zwisler ST, Enggaard TP, Noehr-Jensen L, et al. The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism. Basic Clin Pharmacol Toxicol 2009 Apr; 104: 335-4 g/10.1111/j.1742-7843.2009.00378.x">CrossRef
  
• 作者单位：Anne E. Olesen (1) (2)
  Richard Upton (3)
  David J. R. Foster (4)
  Camilla Staahl (1) (2)
  Lona L. Christrup (5)
  Lars Arendt-Nielsen (2)
  Professor Asbj?rn M. Drewes (1) (2)
  
  1. Mech-Sense, Department of Gastroenterology, Aalborg Hospital, Aarhus University Hospital, Hobrovej 18-22, 9000, Aalborg, Denmark
  2. Center for Sensory-Motor Interactions (SMI), Department of Health Science and Technology, Aalborg University, Aalborg, Denmark
  3. Department of Anesthesia and Intensive Care, Royal Adelaide Hospital, University of Adelaide, Adelaide, South Australia, Australia
  4. School of Pharmacy and Medical Sciences and Sansom Institute, University of South Australia, Adelaide, South Australia, Australia
  5. Department of Pharmacology and Pharmacotherapy, Faculty of Pharmaceutical Sciences, University of Copenhagen, Copenhagen, Denmark
  
• ISSN：1179-1926

文摘

Background and Objective Oxycodone is not as well characterized, with respect to its pharmacokinetic/ pharmacodynamic properties, as other opioids. Moreover, the pharmacodynamic profile of oxycodone can be affected by changes in the pain system, e.g. hyperalgesia. Therefore, the aim of this study was to investigate the pharmacokinetic/pharmacodynamic profiles of oxycodone in a human experimental pain model of hyperalgesia. Methods Twenty-four healthy subjects received oral oxycodone (15 mg) or placebo. Pharmacodynamics were assessed utilizing a multimodal, multi-tissue paradigm where pain was assessed from skin (heat), muscle (pressure) and viscera (heat and electricity) before and 30, 60 and 90 minutes after induction of generalized hyperalgesia evoked by perfusion of acid and capsaicin in the oesophagus. Venous blood samples were obtained for quantification of oxycodone plasma concentrations before and 5, 10, 15, 30, 45, 60, 90 and 120 minutes after drug administration. Results Oxycodone blood concentrations could be described by a one-compartment model but, given the necessarily short timescale of the study, the concentrations were represented by linear interpolation for subsequent pharmacodynamic models. Time-dependent changes in the pain measures in the placebo arm of the study were represented by linear or quadratic functions. The time course of the pain measures in the oxycodone arm was taken to be the time course for the placebo arm plus a concentration-effect relationship that was either zero (no drug effect), linear or a maximum effect (Emax) model. For three of the four pain measures, there was a time-dependent change after administration of placebo (e.g. due to the development of generalized hyperalgesia). Conclusion There was a measurable effect of oxycodone, compared with placebo, on all pain measures, and a linear concentration-effect relationship without an effect delay was demonstrated. This could indicate an initial peripheral analgesic effect of oxycodone.